Vectura News

Discover more about our company, science, innovation and people with the latest headlines from Vectura.

Displaying 62 of 62

Vectura at CPhI North America 2021: July 26 – August 6

Published26/07/2021

Read more
Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury

Published22/06/2021

Read more
Shortlisted for Best Sustainability Reporting: Healthcare

Published15/06/2021

Read more
Vectura announces completion of management buy-out of Lyon oral subsidiary, Skyepharma Production SAS

Published10/06/2021

Read more
Vectura at BIO Digital, June 10-11 & 14-18, 2021

Published09/06/2021

Read more
Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Published06/05/2021

Read more
Showcasing our scientific expertise at Respiratory Drug Delivery Congress (RDD) 4th-7th May, 2021

Published28/04/2021

Read more
Vectura highlights update made by Hikma on launch of generic Advair Diskus®

Published21/04/2021

Read more
“Strategies for rapid progression of inhaled products” at Formulation & Delivery Europe Congress: Online

Published15/04/2021

Read more
Will Downie named in The Medicine Maker’s Power List for 2021

Published15/04/2021

Read more
Vectura Group publishes 2020 preliminary results

Published18/03/2021

Read more
Vectura Expands Dry Powder Inhaler Development and Manufacturing Capabilities at its Facility in Chippenham, U.K.

Published05/03/2021

Read more
Vectura Virtual Audits

Published26/02/2021

Read more
Pre-close trading update confirms 2020 trading ahead of expectations

Published12/01/2021

Read more
Vectura Group appoints Jeanne Hecht and Jeanne Thoma to its Board of Directors

Published30/12/2020

Read more
Vectura provides update on GSK litigation

Published29/12/2020

Read more
Vectura earns $11m milestone as Hikma receives US FDA approval for generic Advair Diskus®

Published17/12/2020

Read more
Vectura Expands Capabilities to Handle and Develop Highly Potent Inhaled Drugs at its Facility in Chippenham, U.K.

Published14/12/2020

Read more
Vectura signs agreement with Kinaset Therapeutics Inc. to support the development of VR588 to treat asthma

Published30/11/2020

Read more
Vectura provides update on GSK litigation

Published19/11/2020

Read more
Will Downie’s podcast: “There’s a patient at the end of every piece of work we do…”

Published08/10/2020

Read more
Vectura shortlisted for ’Excellence in Pharma: Contract Services and Outsourcing’

Published24/09/2020

Read more
Status update on VR315 (US)

Published22/09/2020

Read more
2020 Interim Results

Published15/09/2020

Read more
Vectura partners with Monash University to support development of inhaled oxytocin to prevent postpartum haemorrhage

Published14/09/2020

Read more
Notice of Interim Results

Published06/08/2020

Read more
QVM149 receives regulatory approval in Europe and Japan

Published07/07/2020

Read more
Live Webcast 24th June: Dry Powder Inhalers – Key Considerations for Combination Product Development

Published17/06/2020

Read more
Vectura signs agreement with Aerami Therapeutics Inc.

Published08/06/2020

Read more
Vectura expands business development team with three global appointments

Published03/06/2020

Read more
Podcast: Breathing new life into existing drugs

Published28/05/2020

Read more
Share buyback and AGM trading update

Published27/05/2020

Read more
Podcast: Vectura presents latest science at Digital RDD 2020

Published17/04/2020

Read more
Vectura’s response to the COVID-19 outbreak

Published19/03/2020

Read more
Vectura publishes 2019 preliminary results

Published17/03/2020

Read more
Vectura appoints Mark Bridgewater as Chief Commercial Officer

Published09/03/2020

Read more
Sharon Johnson appointed Executive Vice President for Delivery Management

Published10/02/2020

Read more
Pre-close trading update confirms 2019 trading in-line with expectations

Published13/01/2020

Read more
Meet our inhalation experts at Drug Delivery to the Lungs (DDL) 2019

Published03/12/2019

Read more
VR315US: Hikma submits response to FDA

Published27/11/2019

Read more
Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019

Published22/10/2019

Read more
Vectura Group appoints New Chief Executive Officer

Published15/10/2019

Read more
Results of the General Meeting held on 10th October 2019

Published10/10/2019

Read more
Vectura provides update on GSK litigation

Published13/09/2019

Read more
Vectura delivers strong H1 2019 financial performance

Published10/09/2019

Read more
Proposed increased capital return to shareholders of approx. £60m

Published09/09/2019

Read more
Proposed £50 million capital return and trading update

Published17/07/2019

Read more
Vectura Group Plc announces leadership changes

Published10/06/2019

Read more
QVM149 submission means early $2.5m payment for Vectura

Published24/05/2019

Read more
Vectura data to be shared at ATS 2019

Published15/05/2019

Read more
Vectura wins US GSK patent litigation and awarded $89.7m in damages by jury

Published26/04/2019

Read more
R&D: Transformation frees up more resources for innovation

Published10/04/2019

Read more
Vectura reports strong 2018 financial and operational performance

Published26/03/2019

Read more
Pre-close trading update confirms good progress against 2018 goals

Published03/01/2019

Read more
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio

Published08/11/2018

Read more
Rising to the challenge of developing inhaled generic medicines

Published26/09/2018

Read more
Vectura Group Interim Results for H1 2018

Published11/09/2018

Read more
Fundraising for AsthmaUK

Published06/07/2018

Read more
Bringing nebuliser device and formulation together

Published05/07/2018

Read more
New product creation – from paper to market

Published04/07/2018

Read more
Generic programmes

Published03/07/2018

Read more

Displaying 62 of 62